Butt Hamza Naseer, Arshad Fizza, Asad Muhammad, Wakil Hamza, Zainab Saadia, Anis Roomisa, Kirshan Kumar Sanjay, Sehar Lodhi Sana, Mansoor Mahwash
Acute and General Internal Medicine, Queen Elizabeth University Hospital, Glasgow, GBR.
Medicine and Surgery, Saad Medical Complex, Faisalabad, PAK.
Cureus. 2024 Dec 7;16(12):e75302. doi: 10.7759/cureus.75302. eCollection 2024 Dec.
Introduction Although metabolic dysfunction-associated fatty liver disease (MAFLD) is becoming more common in individuals with hepatocellular carcinoma (HCC), it is still unknown how this condition relates to postoperative complications of HCC. While hepatitis B/C virus (HBV/HCV) infection and alcohol use are primary risk factors, MAFLD has emerged as a significant contributor to HCC incidence. Understanding the prognostic impact of MAFLD on HCC outcomes, particularly post-radical resection, is essential. Objective This study aims to evaluate the prognostic significance of MAFLD on postoperative outcomes in HCC patients, following radical hepatectomy, with a focus on gender-specific mortality differences. Methodology A retrospective cohort study was conducted at Pakistan Navy Station Shifa Hospital, Bahria University Medical and Dental College, Karachi, Pakistan. Consecutive HCC patients who underwent radical resection between May 2023 and April 2024 were included. MAFLD was diagnosed based on hepatic steatosis and metabolic dysfunction criteria. Data on demographics, clinical features, and outcomes were collected from electronic medical records. The primary outcome was overall survival (OS), and the secondary outcomes included recurrence-free survival (RFS). Statistical analyses involved multivariate Cox regression and Kaplan-Meier survival curves using IBM SPSS Statistics for Windows, Version 27 (Released 2020; IBM Corp., Armonk, NY, USA). Results MAFLD patients exhibited higher median body mass index (BMI) (25.3 kg/m² vs. 23.5 kg/m², p < 0.001), increased prevalence of type 2 diabetes mellitus (33.0% vs. 12.0%, p = 0.019), greater metabolic dysregulation (63.0% vs. 17.0%, p < 0.001), and elevated alanine aminotransferase (ALT) levels (38.0 IU/L vs. 32.0 IU/L, p = 0.045) compared to non-MAFLD patients. While OS and RFS rates were marginally better in the MAFLD group, differences were not statistically significant (p > 0.05). Notably, MAFLD significantly increased mortality in female HCC patients, but not in males. Significant predictors of progression included Child-Pugh grade B, tumour size, and microvascular invasion. Conclusion MAFLD does not significantly impact OS or RFS following radical resection of HCC. However, MAFLD is associated with increased mortality in female patients, highlighting the need for gender-specific monitoring and management strategies in MAFLD-related HCC cases. Further large-scale studies are required to confirm these findings and elucidate the underlying mechanisms.
引言 尽管代谢功能障碍相关脂肪性肝病(MAFLD)在肝细胞癌(HCC)患者中越来越常见,但这种情况与HCC术后并发症之间的关系仍不清楚。虽然乙型/丙型肝炎病毒(HBV/HCV)感染和饮酒是主要危险因素,但MAFLD已成为HCC发病的重要促成因素。了解MAFLD对HCC预后的影响,特别是根治性切除术后的影响至关重要。
目的 本研究旨在评估MAFLD对HCC患者根治性肝切除术后预后的意义,重点关注性别特异性死亡率差异。
方法 在巴基斯坦卡拉奇巴哈里亚大学医学院和牙科学院的巴基斯坦海军希法医院进行了一项回顾性队列研究。纳入2023年5月至2024年4月期间接受根治性切除的连续HCC患者。根据肝脂肪变性和代谢功能障碍标准诊断MAFLD。从电子病历中收集人口统计学、临床特征和预后数据。主要结局是总生存期(OS),次要结局包括无复发生存期(RFS)。统计分析采用多变量Cox回归和Kaplan-Meier生存曲线,使用IBM SPSS Statistics for Windows,版本27(2020年发布;IBM公司,美国纽约州阿蒙克)。
结果 与非MAFLD患者相比,MAFLD患者的中位体重指数(BMI)更高(25.3kg/m²对23.5kg/m²,p<0.001),2型糖尿病患病率增加(33.0%对12.0%,p=0.019),代谢失调更严重(63.0%对17.0%,p<0.001),丙氨酸氨基转移酶(ALT)水平升高(38.0IU/L对32.0IU/L,p=0.045)。虽然MAFLD组的OS和RFS率略好,但差异无统计学意义(p>0.05)。值得注意的是,MAFLD显著增加了女性HCC患者的死亡率,但男性患者未增加。进展的显著预测因素包括Child-Pugh B级、肿瘤大小和微血管侵犯。
结论 MAFLD对HCC根治性切除术后的OS或RFS没有显著影响。然而,MAFLD与女性患者死亡率增加有关,这突出了在MAFLD相关HCC病例中需要针对性别的监测和管理策略。需要进一步的大规模研究来证实这些发现并阐明潜在机制。